SCHEMBL6235315

SCHEMBL6235315

O=c1c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2ccccc2n1Cc1cccc(Br)c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.65
HSD17B10 Q99714 1/20 0.65
CYP2C9 P11712 3/20 0.53
NR1I2 O75469 1/20 0.53
POLB P06746 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
RECQL P46063 1/20 0.44
CASP6 P55212 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ERCC5 P28715 2/20 0.39
FEN1 P39748 2/20 0.39
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
CFTR P13569 1/20 0.37
EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733839 0.90 MAPK1 (0.68) MAPK1HSD17B10CYP2C9NR1I2POLB
SCHEMBL1522429 0.88 MAPK1 (0.52) MAPK1HSD17B10CYP2C9NR1I2MEN1
SCHEMBL1522340 0.86 MAPK1 (0.56) MAPK1HSD17B10CYP2C9NR1I2POLB
SCHEMBL6235955 0.86 MAPK1 (0.61) MAPK1HSD17B10CYP2C9NR1I2POLB
SCHEMBL6233389 0.85 MAPK1 (0.69) MAPK1HSD17B10CYP2C9NR1I2POLB
SCHEMBL6738199 0.84 MAPK1 (0.66) MAPK1HSD17B10CYP2C9NR1I2POLB
SCHEMBL6738676 0.84 MAPK1 (0.66) MAPK1HSD17B10CYP2C9NR1I2POLB
SCHEMBL6234470 0.84 MAPK1 (0.63) MAPK1HSD17B10CYP2C9NR1I2POLB
SCHEMBL6237190 0.83 MAPK1 (0.67) MAPK1HSD17B10CYP2C9NR1I2POLB
SCHEMBL6238046 0.83 HSD17B10 (0.72) MAPK1HSD17B10CYP2C9NR1I2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 MAPK1 3699/4885HSD17B10 1428/4885CYP2C9 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.